I’m happy to share that I’m starting a new position as Scientific co-founder LASEREDD Therapeutics" Ross

Self-docking and cross-docking simulations of G protein-coupled receptor-ligand complexes: Impact of of 11 Class A GPCR crystallized in multiple activation states (giving rise to 37 self-docking and 68 cross Our results show that one specific subset of cross-docking simulations gave results of similar quality RMSD values for top-scored poses were 1.2 Å and 2.0 Å for self-docking and StateMatch/FunctionMatch cross-docking

The gross proceeds to Crinetics from the offering, before deducting the underwriting discounts and commissions

Pathophysiology Date & Time Friday, November 3rd / 9:45 AM Abstract Coming Soon Authors and Affiliations Gross JD -1 (lead author, presenter) Kohlenbach LM -2 Zhou Y -1 Marugan JJ -3 Barak LS -1 (senior author) About Joshua Gross "I am a neuropharmacologist interested in exploiting GPCR biased signaling to design pharmacotherapies that improve efficacy and minimize side effects for diet-induced metabolic diseases. " Josh Gross

Ross Cheloha is an Investigator at the National Institutes of Health in the Laboratory of Bioorganic Ross and I chatted about his work and transition to an independent investigator; join me to learn more Ross Cheloha on the web NIDDK Cheloha Lab Google Scholar LinkedIn Twitter ResearchGate Dr.

Ross Cheloha About this episode Dr. Ross Cheloha is an Investigator at the National Institutes of Health in the Laboratory of Bioorganic Ross and I chatted about his work and transition to an independent investigator; join me to learn more Ross Cheloha on the web NIDDK Cheloha Lab Google Scholar LinkedIn Twitter ResearchGate Dr.